Dr. Hamilton Discusses Challenges With Approved Treatments for HER2-Positive Breast Cancer
Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the challenges associated with utilizing new agents in HER2-positive breast cancer.
Many novel agents were recently approved, including T-DM1 (Kadcyla) and pertuzumab (Perjeta). This has made it difficult to determine how to best sequence and use these types of treatments, says Hamilton. There have been approvals for metastatic, neoadjuvant, and adjuvant disease, as well as improvements to the standard treatment trastuzumab (Herceptin).
Hamilton believes the challenges for the next couple of years include figuring out where to sequence the drugs, where to place them, and how best to use them in combination.
Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the challenges associated with utilizing new agents in HER2-positive breast cancer.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
